Pharmaceuticals

Non-injectable Insulin Market Outlook 2025 – Insights for Executive and Strategic Planning

July 2, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Non-injectable Insulin Market Grown from 2024 to 2025?#_x000D_

The market size for non-injectable insulin has seen a swift increase in recent times. Rising from a valuation of $1.92 billion in 2024, it is projected to reach $2.16 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.1%. The historic growth can be credited to factors like better patient compliance, tackling needle fear, improved quality of life, simple administration methods, and consistent control of blood glucose levels._x000D_

_x000D_

#What Growth Rate Is Anticipated for the Non-injectable Insulin Market in the Coming Years?#_x000D_

The market size for non-injectable insulin is predicted to rapidly expand in the following years, reaching a value of $3.17 billion in 2029 with a compound annual growth rate of 10.1%. This projected growth during the forecast period is linked to ongoing focus on patient adherence, constant solutions for needle fear, improvements in life quality, unceasing enhancement of safety measures, and minimised risks associated with infections and injuries. The forecast period will also see principal trends like the advancement in technology, development of tech-based solutions, incorporation of digital health, application of nanotechnology, and combined therapies._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp_x000D_

_x000D_

#Who Are the Leading Companies in the Non-injectable Insulin Market?#_x000D_

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited_x000D_

_x000D_

#What Are the Key Drivers of the Non-injectable Insulin Market?#_x000D_

Anticipated increases in obesity and diabetes cases are projected to spur the expansion of the non-injectable insulin market. Obesity involves the extreme build-up of body fat, typically due to an energy imbalance between calories ingested and output, while diabetes mellitus, commonly known simply as diabetes, includes a set of metabolic disorders marked by sustained high blood sugar levels. Non-injectable insulin serves as a remedy for diabetes and obesity, with the capacity to enhance control by tackling hurdles to insulin treatment, providing potential weight control benefits and more convenient care options. For instance, as per the World Heart Federation, a Switzerland-domiciled NGO, the global prevalence of obesity is predicted to escalate, with approximately 2.3 billion people in 2021, children and adults included, struggling with being overweight and obesity that’s expected to increase to 2.7 billion by 2025. In addition, in April 2023, a study by the British Diabetic Association, a UK diabetes charity, reported that 4.3 million individuals in the UK have diabetes and over 2.4 million dwellers are at a high risk of developing type 2 diabetes. The enrolment numbers for 2021-22 displayed an increase of 148,951 from the prior year. Consequently, surging obesity and diabetes problems are stimulating the expansion of the non-injectable insulin market._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=13888&type=smp_x000D_

_x000D_

#What Are the Key Market Segments in the Non-injectable Insulin Industry?#_x000D_

The non-injectable insulin market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Synthetic Insulin, Semi Synthetic Insulin_x000D_

2) By Product: Pills, Sprays, Other Products_x000D_

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores_x000D_

_x000D_

Subsegments:_x000D_

1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin_x000D_

2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations_x000D_

_x000D_

#What Are the Latest Trends in the Non-injectable Insulin Market?#_x000D_

Leading firms in the non-injectable insulin industry are concentrating on the development of innovative drug delivery technologies such as needle-free insulin sprays. They’re aimed at enhancing the quality of life for diabetic patients who require frequent insulin injections. A needle-free insulin spray is a hassle-free and painless alternative for blood glucose control and can be conveniently sprayed directly into the mouth. NiedlFree Technologies, a technology company based in India, launched an oral insulin spray called Ozulin in November 2023. Ozulin is aimed at being more user-friendly, especially for people with diabetes who may find conventional insulin injection methods difficult. If it gets approval, Ozulin could significantly transform the diabetes care market by providing a less painless and more convenient alternative to insulin injections._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report_x000D_

_x000D_

#What Are the Key Regional Markets in the Non-injectable Insulin Industry?#_x000D_

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13888_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the non-injectable insulin market, and how is it changing globally?_x000D_

2. Who are the major companies in the non-injectable insulin market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the non-injectable insulin market right now?_x000D_

4. Which products or customer segments are growing the most in the non-injectable insulin market?_x000D_

5. What factors are helping or slowing down the growth of the non-injectable insulin market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_